RhumbLine Advisers’s Purple Biotech PPBT Stock Holding History

RhumbLine Advisers’s Portfolio PPBT Stock Details PPBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44K	Buy	856 +146	+21%	+$492	﹤0.01%	4016
2026 Q1	$2.87K	Sell	710 -29	-4%	-$157	﹤0.01%	3913
2025 Q4	$4.86K	Buy	739 +631	+584%	+$4.58K	﹤0.01%	3926
2025 Q3	$614	Hold	108	–	–	﹤0.01%	4052
2025 Q2	$2.55K	Buy	108 +27	+33%	+$667	﹤0.01%	3974
2025 Q1	$2.19K	Buy	81 +20	+33%	+$639	﹤0.01%	3982
2024 Q4	$2.84K	Buy	+61	New	+$2.35K	﹤0.01%	4010
2024 Q3	–	Hold	0	–	-$6	–	4302
2024 Q2	–	Hold	0	–	–	–	4364
2024 Q1	–	Sell	-3	Closed	-$430	–	4248
2023 Q4	$432	Hold	3	–	–	﹤0.01%	4205
2023 Q3	$638	Hold	3	–	–	﹤0.01%	4217
2023 Q2	$777	Buy	+3	New	+$1.08K	﹤0.01%	4296

Other funds holding PPBT

SmartHarvest Portfolios Poulsbo, Washington $309M AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

IFG Advisory Atlanta, Georgia $2.85B AUM 26.07% 1-Year Est. Return

RhumbLine Advisers's PPBT Position: Q2 2026 in Review

RhumbLine Advisers increased its Purple Biotech (PPBT) stake by 21% in Q2 2026, buying an estimated $492 and bringing the position to 856 shares worth $1.44K. The position accounts for ﹤0.01% of the portfolio, ranked #4016.

RhumbLine Advisers first reported a position in PPBT in Q2 2023 and has held it in 10 quarters since. The position peaked at $4.86K in Q4 2025. 13 funds tracked by Wall St. Rank hold PPBT as of Q2 2026.

RhumbLine Advisers held 856 shares of Purple Biotech worth $1.44K as of Q2 2026.
RhumbLine Advisers bought 146 Purple Biotech shares in Q2 2026, an estimated $492.
Purple Biotech made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #4016 holding.
RhumbLine Advisers first reported a position in Purple Biotech in Q2 2023 and has held it in 10 quarters since.
RhumbLine Advisers's Purple Biotech position peaked at $4.86K in Q4 2025.
13 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.